Sarsasapogenin

Drug Profile

Sarsasapogenin

Alternative Names: Cogane; JNX-1001; PYM-50028; Smilagenin

Latest Information Update: 26 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Phytopharm
  • Developer IXICO
  • Class Antidementias; Herbal medicines; Neuroprotectants; Nootropics; Small molecules; Steroid sapogenins
  • Mechanism of Action Brain derived neurotrophic factor agonists; Glial cell line-derived neurotrophic factor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alzheimer's disease; Amyotrophic lateral sclerosis; Glaucoma; Parkinson's disease

Most Recent Events

  • 23 May 2013 Phytopharm conducts discussions with external parties for further development of sarsasapogenin under licensing arrangements
  • 28 Feb 2013 Efficacy data from the phase II CONFIDENT-PD trial in Parkinson's disease released by Phytopharm
  • 18 Apr 2012 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by Phytopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top